Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Lipid levels in the blood are proposed to play a role in the progression of diabetic
retinopathy. Lipid levels can be controlled with dyslipidemic drugs, such as fenofibrate.
Fenofibrate is known to prevent diabetic microvascular complications by decreasing
cholesterol and triglyceride levels. This study aims to investigate the effects of oral
fenofibrate on central macular thickness (CMT) and macular volume, as well as on specific
biomarkers of endothelial dysfunction (eNOS), inflammation (VCAM-1), and angiogenesis (VEGF)
in DR individuals with dyslipidemia.